Literature DB >> 23780798

A nanosystem for water-insoluble drugs prepared by a new technology, nanoparticulation using a solid lipid and supercritical fluid.

Joo Won Park1, Jeong Min Yun, Eun Seong Lee, Yu Seok Youn, Kab Sig Kim, Young Taik Oh, Kyung Teak Oh.   

Abstract

While the number and diversity of lead compounds has increased with the development of science technologies, ca. 90 % of new chemical entities under development have shown low aqueous solubility, classified as class II or IV of the biopharmaceutics classification system (BCS). The low aqueous solubility hinders their clinical translations due to low bioavailability and dissolution-limited absorption of orally-administered drugs. Several technologies have been employed to improve the solubility of poorly water-soluble drugs. In this paper, a new method of nanoparticulation using fat and a supercritical fluid (NUFS) for the formulation of hydrophobic drugs was applied to solve the low solubility problem. A typical BCS class II drug, itraconazole, was selected and formulated with hydroxypropyl methylcellulose, emulsification, and anticoagulating agents for NUFS. The non-spherical itraconazole nanoparticles prepared by NUFS were ~300-500 nm in size with a ~15-fold improved dissolution rate compared to non-nanoparticles of itraconazole (i.e., raw itraconazole). In addition, a high drug content of ~46 % by weight and a drug loading efficiency greater than 85 % were achieved. Therefore, the new technology for nano-platforms could be a promising solution for solubilization of poorly water-soluble drugs, resulting in improved bioavailability.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23780798     DOI: 10.1007/s12272-013-0187-2

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  2 in total

Review 1.  Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.

Authors:  Ranjith Kumar Kankala; Yu Shrike Zhang; Shi-Bin Wang; Chia-Hung Lee; Ai-Zheng Chen
Journal:  Adv Healthc Mater       Date:  2017-07-28       Impact factor: 9.933

2.  Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.

Authors:  Dong Ha Kim; Yun Jung Choi; Ki Jung Sung; Seon-A Yoo; Young Hoon Sung; Jeong Kon Kim; Chang-Min Choi; Miyong Yun; Eun Yong Lee; Yong Suk Jin; Seungho Cook; Jin Kyung Rho; Jae Cheol Lee
Journal:  Mol Oncol       Date:  2018-11-02       Impact factor: 6.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.